Εμβληματικές επενδύσεις στην Τρίπολη με ισχυρό εθνικό και ευρωπαϊκό αποτύπωμα – Η ελληνική φαρμακοβιομηχανία στην αιχμή της αναπτυξιακής στρατηγικής της χώρας Με ιδιαίτερη επιτυχία ολοκληρώθηκε η επίσκεψη του Πρωθυπουργού, κ. Κυριάκου Μητσοτάκη, την Τρίτη 28 Απριλίου 2026, στη Βιομηχανική Περιοχή Τρίπολης, στις στρατηγικές επενδύσεις των εταιρειών DEMO, Win Medica (Ομίλου ELPEN) και FARAN, παρουσία του […..]
Δείτε εδώ το αναλυτικό πρόγραμμα
Project Code: ΤΑCL1-0496261 Project Title: INDUSTRIAL RESEARCH FOR THE DEVELOPMENT OF NINTEDANIB ORAL SOLUTION Project budget 1.250.000,00 € EU funding 750.000,00 € The objective of the R&D project implemented in the framework of the action “Reform of the clawback system and offsetting it with research and investment costs” of the Recovery and Resilience Fund […..]
According to the FortuneGreece‘s list of the 30 fastest-growing companies in Greece in 2022, “Looking at this year’s list, the pharmaceutical company FARAN SA is in first place in the general ranking with the third highest average rate of change in Earnings before Taxes – Interest and Depreciation – EBITDA (90.8%) and the fifth highest […..]
The historic pharmaceutical company FARAN is one of the fastest growing companies in the industry, recording an impressive increase in turnover, as Marios Katsikas, President & CEO of FARAN, tells us, answering the first question about the company’s course: In 2022, we are running with a 30% increase, which is impressive, but it becomes even […..]
The Greek pharmaceutical industry FARAN is one of the fastest growing companies in the industry. With a model that combines branded generics of our own and important original products from international firms, we continue our upward course, as in recent years we have recorded a significant increase in turnover, 40% in 2020, 21% in 2021 […..]